Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence

International Journal of Urology

Volumn 7, Issue 6, 2000, Pages 210-217

  Wu, Xiu Xian ^a   Kakehi, Yoshiyuki ^a   Takahashi, Takeshi ^a   Habuchi, Tomonori ^b   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; Intravesical recurrence; Telomeric repeat amplification protocol (TRAP) assay; Urinary telomerase activity

Indexed keywords

TELOMERASE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; URINE; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TELOMERASE; URINARY BLADDER NEOPLASMS;

EID: 0034073125     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2000.00178.x     Document Type: Article

References (22)

1. 1 Fitzpatrick JM, West AR, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grade 1 and 2): The importance of recurrence pattern following initial resection. J. Urol. 1986; 135: 920-2.
2. 2 England HR, Paris AMI, Blandy JP. The correlation of T1 bladder tumor history with prognosis and follow-up requirements. Br. J. Urol. 1981; 53: 593-7.
3. 3 Takahashi T, Habuchi T, Kakehi Y et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. 1998; 58: 5835-41.
4. 4 Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989; 59: 521-9.
5. 5 Blackburn EH. Telomeres and their synthesis. Science 1990; 249: 489-90.
6. 6 Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-73.
7. 7 Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-15.
8. 8 Piatyszek MA, Kim NM, Weinrich SL et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Science 1995; 17: 1-15.
9. 9 Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85: 2315-20.
10. 10 Harle-Bachor C, Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal andancarcinoma-derived skin keratinocytes. Proc. Natl Acad Sci. USA 1996; 93: 6476-81.
11. 11 Kinoshita H, Ogawa O, Kakehi Y et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J. Natl Cancer Inst. 1997; 89: 724-30.
12. 12 Lin H, Miyamoto H, Fujinami K et al. Telomerase activity in human bladder cancer. Clin. Cancer Res. 1996; 2: 929-32.
13. 13 Akao T, Kakehi Y, Wu X-X et al. Semi-quantitative analysis of telomerase activity of exfoliated cells in urine of patients with urothelial cancer: Causative factors affecting sensitivity and specificity. Urol. Oncol. 1997; 3: 118-24.
14. 14 Yoshida K, Sugino T, Tahara H et al. Telomerase activity in bladder carcinoma and its implication for non-invasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997; 79: 362-9.
15. 15 Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerasc activity. Cancer 1998; 82: 708-14.
16. 16 Beck S, O'Keeffe T, Coull JM, Koster H. Chemiluminescent detection of DNA. Application for DNA sequencing and hybridization. Nucl. Acids Res. 1989; 17: 5115-22.
17. 17 Oosterlinck W, Kurth KH, Schröder et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethrul resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol. 1993; 149: 749-52.
18. 18 Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: A prospective, randomized, double-blind, controlled trial. J. Urol. 1983; 129: 505-9.
19. 19 Griffiths TR, Brotherick I, Bishop RI et al. Cell adhesion molecules in bladder cancer: Soluble serum E-cadherin correlates with predictors of recurrence. Br. J. Cancer 1996; 74: 579-84.
20. 20 Syrigos KN, Harrington K, Waxman J, Krausz T, Pignatelli M. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J. Urol. 1998; 160: 1889-93.
21. 21 Crew JP, O'Brien T, Bradburn M et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997; 57: 5281-5.
22. 22 Stavropoulos NE, Ioachim E, Hastazeris K, Goussia A, Agnantis NJ. Lymphocyte subsets in superficial bladder cancer: Correlation with biological activity of the tumors. Anticancer Res. 1998; 18: 2037-40.